This finding is reminiscent of the recent report that PARPi co-opts MEK as a resistance mechanism in KRAS-mutant ovarian, lung and colon cancer [53], further underscoring the similarity between MPM and RAS-driven cancer. This evidence concerns the gene KRAS and colonic neoplasm.